Clover Health Investments (NASDAQ:CLOV - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Clover Health Investments to post earnings of ($0.03) per share for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.
Clover Health Investments (NASDAQ:CLOV - Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.05. The company had revenue of $356.26 million for the quarter, compared to the consensus estimate of $338.70 million. Clover Health Investments had a negative net margin of 7.30% and a negative return on equity of 36.55%. During the same quarter last year, the firm posted ($0.06) EPS. On average, analysts expect Clover Health Investments to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Clover Health Investments Stock Performance
NASDAQ CLOV remained flat at $4.05 during trading on Wednesday. 3,994,594 shares of the company's stock were exchanged, compared to its average volume of 8,004,715. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of -11.91 and a beta of 2.13. The company has a 50-day simple moving average of $3.33 and a 200 day simple moving average of $2.00. Clover Health Investments has a 1-year low of $0.61 and a 1-year high of $4.71.
Analyst Upgrades and Downgrades
Separately, UBS Group began coverage on Clover Health Investments in a report on Monday, October 7th. They set a "neutral" rating and a $4.00 target price for the company.
Get Our Latest Research Report on CLOV
Clover Health Investments Company Profile
(
Get Free Report)
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.
See Also
Before you consider Clover Health Investments, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clover Health Investments wasn't on the list.
While Clover Health Investments currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
